α-Alkyl Substituted Pirinixic Acid Derivatives as Potent Dual Agonists of the Peroxisome Proliferator Activated Receptor Alpha and Gamma
作者:Oliver Rau、Yvonne Syha、Heiko Zettl、Michael Kock、Andreas Bock、Manfred Schubert-Zsilavecz
DOI:10.1002/ardp.200700209
日期:2008.3
Peroxisome proliferator‐activated receptors (PPAR) are nuclear receptors, playing a pivotal role in energy homeostasis. Activators of the PPARα subtype are in widespread use for the treatment of hyperlipidemia, while activators of the PPARγ subtype are in clinical use for the treatment of type‐2 diabetes. Since both of these diseases are frequently associated, the combined treatment with one drug simultaneously
过氧化物酶体增殖物激活受体 (PPAR) 是核受体,在能量稳态中起关键作用。PPARα 亚型激活剂广泛用于治疗高脂血症,而 PPARγ 亚型激活剂在临床上用于治疗 2 型糖尿病。由于这两种疾病经常相互关联,因此用一种同时激活 PPARα 和 PPARγ 的药物进行联合治疗似乎是值得的。从吡立昔酸开始,它是一种中等活性的双 PPARα/γ 激动剂,我们通过用脂肪链取代 α- 位来提高对人 PPARα 和 PPARγ 的效力。分别在四个碳和六个碳的链长处达到最大效果,导致 PPARα 的活性诱导因子分别为 36 和 PPARγ 的因子为 18。